ProPhase Labs (NASDAQ:PRPH) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

ProPhase Labs, Inc. (NASDAQ:PRPH) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.44 and traded as low as $0.1301. ProPhase Labs shares last traded at $0.1356, with a volume of 68,986 shares trading hands.

ProPhase Labs Price Performance

The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of 0.14. The firm’s 50-day moving average is $0.11 and its 200-day moving average is $0.42. The company has a market cap of $662,420.00, a PE ratio of -0.03 and a beta of 0.09.

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRPH. XTX Topco Ltd purchased a new stake in ProPhase Labs in the second quarter worth $40,000. Accretive Wealth Partners LLC purchased a new stake in ProPhase Labs in the third quarter worth $114,000. Finally, Susquehanna International Group LLP grew its stake in ProPhase Labs by 290.1% in the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after purchasing an additional 295,899 shares during the period. 9.45% of the stock is owned by hedge funds and other institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.